Evidence map›Paper›PMID 36678860›Full record

ReviewPharmaceutics2023

Genetically Encoded Self-Assembling Protein Nanoparticles for the Targeted Delivery In Vitro and In Vivo.

Anastasiia S Obozina, Elena N Komedchikova, Olga A Kolesnikova, Anna M Iureva, Vera L Kovalenko, Fedor A Zavalko, Tatiana V Rozhnikova, Ekaterina D Tereshina, Elizaveta N Mochalova, Victoria O Shipunova

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anastasiia S ObozinaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Elena N KomedchikovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.ORCID 0000-0002-5115-3774
Olga A KolesnikovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Anna M IurevaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Vera L KovalenkoMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Fedor A ZavalkoMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Tatiana V RozhnikovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Ekaterina D TereshinaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.
Elizaveta N MochalovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.ORCID 0000-0002-3157-7158
Victoria O ShipunovaMoscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.ORCID 0000-0001-6361-1042
Moscow Institute of Physics and Technology · RU

Funding

Ministry of Science and Higher Education of the Russian Federation "Priority 2030", agreement 075-02-2021-1316 30.09.2021Russian Science Foundation 22-73-10141
6 · The paper itself

Abstract

Targeted nanoparticles of different origins are considered as new-generation diagnostic and therapeutic tools. However, there are no targeted drug formulations within the composition of nanoparticles approved by the FDA for use in the clinic, which is associated with the insufficient effectiveness of the developed candidates, the difficulties of their biotechnological production, and inadequate batch-to-batch reproducibility. Targeted protein self-assembling nanoparticles circumvent this problem since proteins are encoded in DNA and the final protein product is produced in only one possible way. We believe that the combination of the endless biomedical potential of protein carriers as nanoparticles and the standardized protein purification protocols will make significant progress in "magic bullet" creation possible, bringing modern biomedicine to a new level. In this review, we are focused on the currently existing platforms for targeted self-assembling protein nanoparticles based on transferrin, lactoferrin, casein, lumazine synthase, albumin, ferritin, and encapsulin proteins, as well as on proteins from magnetosomes and virus-like particles. The applications of these self-assembling proteins for targeted delivery in vitro and in vivo are thoroughly discussed, including bioimaging applications and different therapeutic approaches, such as chemotherapy, gene delivery, and photodynamic and photothermal therapy. A critical assessment of these protein platforms' efficacy in biomedicine is provided and possible problems associated with their further development are described.

Indexed as

albumincaseinencapsulinlactoferrinlumazine synthasemagic bulletprotein nanoparticlesself-assemblytargeted deliverytransferrin

Identifiers

PMID36678860
PMCPMC9861179
OpenAlexW4315628497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.